ASCO22: Breast cancer research by Meredith Regan, ScD
Dana-Farber's Meredith Regan, ScD presents research looking at early treatment effects of adjuvant endocrine therapy for high-risk breast cancer at
#ASCO22. it's been challenging to interpret the inconsistent results reported for recent clinical trials testing the addition of a c D K 46 inhibitor to standard endocrine therapy in the context of historical endocrine therapy trials. Because recent trials have a much more narrowly defined high risk patient population that historically enrolled and a narrow time window with first results reported after a median follow up less than two years versus historically close to five years at first report. So when we re analyzed a similar high risk patient population in three practice changing clinical trials demonstrating the benefit of treating with five years aromatase inhibitor versus five years tamoxifen. We saw historically in all three trials, the magnitude of benefit of Ai vs Tampa after two years was similar to the results of adding advocacy to K46 inhibitor to standard endocrine therapy and specifically in the monarchy trial results which led to approval of advent Obama cycling standard therapy. Then historically the early benefit of Ai vs Tam persisted after five years. In contrast to the recent Penelope B trial results, which it seemed early two year benefit that had disappeared by four years and finally the historical patterns of when the recurrences occurred in the patient population was somewhat different across the three reanalyzed trials, especially in the early years, which highlighted that in our planning and interpretation, we need to consider the standard endocrine therapy backbone, which is selected by the physician and patient upon which the new therapy is added and assessed in the clinical trial and we must maintain the long term follow up of attachment endocrine therapy trials to ensure that early treatment benefits persist as long term benefits for patients.